Product introduction

    Platelet aggregation is not only an important process of physiological hemostasis, but also an important mechanism for the formation of pathological thrombus. Clopidogrel is an oral antiplatelet drug, and it can be used to prevent and treat some complications such as myocardial infarction, ischemic cerebral thrombosis, obliterans, atherosclerosis and thromboembolism. Different individuals have different responsiveness to clopidogrel. About 40% of the Asian patients still show residual platelet aggregation after treatment. That is so-called "clopidogrel resistance". In January 2009, FDA first pointed out  the individual differences in the metabolism of clopidogrel is related to metabolism genes and the interaction with other drugs.

Intended for

1. Primary and secondary prevention for acute coronary syndromes, coronary stenting and coronary heart disease.

2, Ischemic cerebral apoplexy

3, Occluded vasculitis

4. Complications caused by atherosclerosis and thromboembolism